Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025
Repare Therapeutics Inc. is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right structure that could unlock additional upside over the coming decade. Repare Therapeutics+1 As of this afternoon’s session, RPTX is changing hands around the low‑$2 range, not far above the estimated US$1.82 per‑share cash consideration embedded in the deal, and up close to 30% versus pre‑announcement levels, reflecting a classic “takeover‑arbitrage” trading pattern. Nasdaq+1
